Skip to main content
Equibles
KRRO logo

KRRO · Korro Bio, Inc.

Track KRRO — free

Use KRRO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KRRO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.06 -0.13 (-0.95%) At close · Aug 24
Market Cap
$194.53M
Shares
14.73M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.18 Open$13.02 Day$13.02–13.56 52W close$5.28–51.36 Avg vol 30d130K Short int1.4M · 9.8% float · 9.2d Short vol65% Last earningsAug 6, 2026 DataNov 2023–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Nov 6, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.9 · calm Equity put/call 0.68
Technical
price trend
Strong Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +11%
above
Price vs 50-day avg +5%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 17%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +24%
trailing
6-month return +15%
trailing
YTD return +65%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +20 funds added
Insider flow Distributing
Net -$360.3K over 90 days · 83% sells
Short interest Falling
9.77% of float · ▼ -1.4% MoM · 9.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
107 holders — near 2-yr high, broad support
Squeeze score 79
high risk · 0–100
Fundamentals
Fair
Revenue growth +181%
Y/Y
EPS growth −33%
Y/Y
Free cash flow $-79.1M
Balance sheet $11.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 121%
annualized · 1-yr
Max drawdown −90%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the 8-K filed May 7, 2025
Restructuring charges · the second quarter of 2025 $1.2M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
17% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) Golden cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +20 funds added
Insider flow Distributing
Net -$360.3K over 90 days · 83% sells
Short interest Falling
9.77% of float · ▼ -1.4% MoM · 9.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
107 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $13 · 17% Range high $51
vs 200-day avg +11% vs 50-day avg +5% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KRRO
Korro Bio, Inc.
this stock
$194.53M +64.5% +181.5% — 9.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.30B +8.1% +20.8% 20.5 3.3%
ARGX
Argenx SE
 $64.66B +20.2% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
107
% held
98.9%
Net QoQ
+1.3M sh
Top holder
Lynx1 Capital Management…
Held Float
View
Held by Funds
Fund positions
90
View
Short & Settlement
Short Interest Falling
Shares short
1.4M
Days to cover
9.2d
Change
-20.7K sh
View
Short Volume
Short vol %
65%
As of
Aug 24, 2026
Short Total
View
Fails to Deliver
FTD shares
3.2K
Value
$33.3K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
37.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$360.3K
Buyers / Sellers
1 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$6.4M
Net income (FY)
$-117.3M
EPS diluted
$-12.48
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 19, 2026
This year
13
View
Proposed Sales
Value
$662.9K
Shares
5.8K
Filed
Aug 4, 2026
View
Exempt Offerings
Offering
$42.3M
Filed
Jul 27, 2020
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View

Performance

Raw-price comparisons begin at the captured split on Nov 6, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
KRRO -0.8% +23.9% +14.6% +27.1% +64.5%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +0.6% +20.2% +3.1% +24.6% +52.3%
Key facts CIK 1703647 CUSIP 500946108 13F (30d) 102 filings 97 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)